Pulmatrix, Inc. is a biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs.
BörsenkürzelPULM
Name des UnternehmensPulmatrix Inc
IPO-datumMar 21, 2014
CEOLudlum (Peter B)
Anzahl der mitarbeiter2
WertpapierartOrdinary Share
GeschäftsjahresendeMar 21
Addresse945 Concord Street
StadtFRAMINGHAM
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl01701
Telefon18883554440
Websitehttps://www.pulmatrix.com/
BörsenkürzelPULM
IPO-datumMar 21, 2014
CEOLudlum (Peter B)
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten